Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sandra M Swain

Showing results (151-160 of 210) with videos related to

Pageof 21
Sort By:
Clinical Breast Cancer|June 21, 2011
Concurrent bevacizumab with a sequential regimen of doxorubicin and cyclophosphamide followed by docetaxel and capecitabine as neoadjuvant therapy for HER2- locally advanced breast cancer: a phase II trial of the NSABP Foundation Research GroupPriya Rastogi, Marc E Buyse, Sandra M Swain, et al.
Breast Cancer Research and Treatment|January 14, 2016
The TRAIL receptor agonist drozitumab targets basal B triple-negative breast cancer cells that express vimentin and AxlJennifer L Dine, Ciara C O'Sullivan, Donna Voeller, et al.
Anti-Cancer Drugs|August 24, 2013
Absence of pharmacokinetic drug-drug interaction of pertuzumab with trastuzumab and docetaxelJavier Cortés, Sandra M Swain, Iveta Kudaba, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 2005
Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31Elizabeth Tan-Chiu, Greg Yothers, Edward Romond, et al.
NPJ Breast Cancer|September 26, 2017
Video intervention increases participation of black breast cancer patients in therapeutic trialsBrandi N Robinson, Antoinette F Newman, Eshetu Tefera, et al.
Breast Cancer Research and Treatment|January 5, 2021
Long-term follow-up assessment of cardiac safety in SAFE-HEaRt, a clinical trial evaluating the use of HER2-targeted therapies in patients with breast cancer and compromised heart functionKatia Khoury, Filipa Lynce, Ana Barac, et al.
Breast Cancer Research and Treatment|September 20, 2022
Molecular characterization of ESR1 variants in breast cancerArielle L Heeke, Andrew Elliott, Rebecca Feldman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 7, 2015
Intrinsic subtypes, PIK3CA mutation, and the degree of benefit from adjuvant trastuzumab in the NSABP B-31 trialKatherine L Pogue-Geile, Nan Song, Jong-Hyeon Jeong, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 22, 2014
Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831Edith A Perez, Edward H Romond, Vera J Suman, et al.
Journal of the National Cancer Institute|February 16, 2026
Sex-based prognosis in industry-sponsored advanced solid tumour trials: an individual participant data meta-analysis of survival and adverse eventsRakchha Chhetri, Natansh D Modi, Bradley D Menz, et al.
Pageof 21

Showing results (151-160 of 210) with videos related to

Sort By:
Pageof 21
Clinical Breast Cancer|June 21, 2011
Concurrent bevacizumab with a sequential regimen of doxorubicin and cyclophosphamide followed by docetaxel and capecitabine as neoadjuvant therapy for HER2- locally advanced breast cancer: a phase II trial of the NSABP Foundation Research GroupPriya Rastogi, Marc E Buyse, Sandra M Swain, et al.
Breast Cancer Research and Treatment|January 14, 2016
The TRAIL receptor agonist drozitumab targets basal B triple-negative breast cancer cells that express vimentin and AxlJennifer L Dine, Ciara C O'Sullivan, Donna Voeller, et al.
Anti-Cancer Drugs|August 24, 2013
Absence of pharmacokinetic drug-drug interaction of pertuzumab with trastuzumab and docetaxelJavier Cortés, Sandra M Swain, Iveta Kudaba, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 2005
Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31Elizabeth Tan-Chiu, Greg Yothers, Edward Romond, et al.
NPJ Breast Cancer|September 26, 2017
Video intervention increases participation of black breast cancer patients in therapeutic trialsBrandi N Robinson, Antoinette F Newman, Eshetu Tefera, et al.
Breast Cancer Research and Treatment|January 5, 2021
Long-term follow-up assessment of cardiac safety in SAFE-HEaRt, a clinical trial evaluating the use of HER2-targeted therapies in patients with breast cancer and compromised heart functionKatia Khoury, Filipa Lynce, Ana Barac, et al.
Breast Cancer Research and Treatment|September 20, 2022
Molecular characterization of ESR1 variants in breast cancerArielle L Heeke, Andrew Elliott, Rebecca Feldman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 7, 2015
Intrinsic subtypes, PIK3CA mutation, and the degree of benefit from adjuvant trastuzumab in the NSABP B-31 trialKatherine L Pogue-Geile, Nan Song, Jong-Hyeon Jeong, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 22, 2014
Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831Edith A Perez, Edward H Romond, Vera J Suman, et al.
Journal of the National Cancer Institute|February 16, 2026
Sex-based prognosis in industry-sponsored advanced solid tumour trials: an individual participant data meta-analysis of survival and adverse eventsRakchha Chhetri, Natansh D Modi, Bradley D Menz, et al.
Pageof 21